Charles Schwab’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-365,428
| Closed | -$21.5M | – | 3560 |
|
|
2023
Q4 | $21.5M | Buy |
365,428
+21,986
| +6% | +$1.24M | 0.01% | 1561 |
|
|
2023
Q3 | $15M | Sell |
343,442
-92,606
| -21% | -$3.31M | ﹤0.01% | 1681 |
|
|
2023
Q2 | $15.8M | Buy |
436,048
+5,554
| +1% | +$229K | ﹤0.01% | 1661 |
|
|
2023
Q1 | $16M | Sell |
430,494
-1,469
| -0.3% | -$66.1K | ﹤0.01% | 1628 |
|
|
2022
Q4 | $19.6M | Buy |
431,963
+27,789
| +7% | +$1.8M | 0.01% | 1463 |
|
|
2022
Q3 | $28.2M | Buy |
404,174
+11,274
| +3% | +$834K | 0.01% | 1142 |
|
|
2022
Q2 | $26.4M | Sell |
392,900
-58
| -0% | -$3.69K | 0.01% | 1192 |
|
|
2022
Q1 | $32.3M | Buy |
392,958
+10,529
| +3% | +$1.08M | 0.01% | 1174 |
|
|
2021
Q4 | $56.1M | Buy |
382,429
+35,404
| +10% | +$5.5M | 0.02% | 821 |
|
|
2021
Q3 | $61.4M | Buy |
347,025
+4,757
| +1% | +$765K | 0.02% | 732 |
|
|
2021
Q2 | $55.3M | Sell |
342,268
-74,530
| -18% | -$12M | 0.02% | 796 |
|
|
2021
Q1 | $71.4M | Buy |
416,798
+11,135
| +3% | +$2.2M | 0.03% | 626 |
|
|
2020
Q4 | $89.1M | Buy |
405,663
+57,335
| +16% | +$12.4M | 0.04% | 463 |
|
|
2020
Q3 | $57.8M | Buy |
348,328
+87,073
| +33% | +$11.9M | 0.03% | 590 |
|
|
2020
Q2 | $29.8M | Buy |
261,255
+33,119
| +15% | +$3.21M | 0.01% | 899 |
|
|
2020
Q1 | $17.5M | Buy |
228,136
+33,085
| +17% | +$2.97M | 0.01% | 1098 |
|
|
2019
Q4 | $25.1M | Buy |
195,051
+5,280
| +3% | +$509K | 0.01% | 1054 |
|
|
2019
Q3 | $14.8M | Buy |
189,771
+9,465
| +5% | +$888K | 0.01% | 1343 |
|
|
2019
Q2 | $18.6M | Buy |
180,306
+10,992
| +6% | +$856K | 0.01% | 1187 |
|
|
2019
Q1 | $12.4M | Buy |
169,314
+15,988
| +10% | +$1.09M | 0.01% | 1449 |
|
|
2018
Q4 | $6.5M | Sell |
153,326
-794
| -0.5% | -$31.6K | 0.01% | 1741 |
|
|
2018
Q3 | $7.26M | Buy |
154,120
+110,863
| +256% | +$6.17M | ﹤0.01% | 1842 |
|
|
2018
Q2 | $2.13M | Buy |
43,257
+35,499
| +458% | +$1.34M | ﹤0.01% | 2358 |
|
|
2018
Q1 | $239K | Buy |
+7,758
| New | +$215K | ﹤0.01% | 2947 |
|
|
2017
Q2 | – | Sell |
-19,648
| Closed | -$103K | – | 3150 |
|
|
2017
Q1 | $103K | Buy |
19,648
+1,600
| +9% | +$8.77K | ﹤0.01% | 3013 |
|
|
2016
Q4 | $86K | Hold |
18,048
| – | – | ﹤0.01% | 3052 |
|
|
2016
Q3 | $120K | Hold |
18,048
| – | – | ﹤0.01% | 2999 |
|
|
2016
Q2 | $99K | Hold |
18,048
| – | – | ﹤0.01% | 3056 |
|
|
2016
Q1 | $387K | Hold |
18,048
| – | – | ﹤0.01% | 2682 |
|
|
2015
Q4 | $571K | Buy |
18,048
+3,800
| +27% | +$134K | ﹤0.01% | 2599 |
|
|
2015
Q3 | $491K | Hold |
14,248
| – | – | ﹤0.01% | 2632 |
|
|
2015
Q2 | $449K | Buy |
14,248
+3,748
| +36% | +$110K | ﹤0.01% | 2712 |
|
|
2015
Q1 | $308K | Hold |
10,500
| – | – | ﹤0.01% | 2827 |
|
|
2014
Q4 | $195K | Hold |
10,500
| – | – | ﹤0.01% | 2987 |
|
|
2014
Q3 | $184K | Hold |
10,500
| – | – | ﹤0.01% | 2974 |
|
|
2014
Q2 | $210K | Buy |
+10,500
| New | +$203K | ﹤0.01% | 2985 |
|
Other funds holding MRTX
Charles Schwab's MRTX Position: Q1 2024 in Review
Charles Schwab sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 365,428 shares — an estimated $21.5M sold.
Charles Schwab first reported a position in MRTX in Q2 2014 and held it in 36 quarters. The position peaked at $89.1M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Charles Schwab reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Charles Schwab sold 365,428 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $21.5M.
- Charles Schwab first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 36 quarters.
- Charles Schwab's Mirati Therapeutics, Inc. Common Stock position peaked at $89.1M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.